Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lifitegrast ophthalmic solution Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

NCT04354545
View directory record Official record
Conditions
Glaucoma, Ocular Surface Disease
Interventions
Xiidra (Lifitegrast ophthalmic solution) 5%
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Lifitegrast to Treat Dry Eye

NCT01636206
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Artesia, California • Hemet, California • Laguna Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

NCT02284516
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Withdrawn Phase 4 Interventional

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

NCT03431272
View directory record Official record
Conditions
Contact Lens Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

NCT01743729
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Artesia, California • Hemet, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Terminated Not applicable Interventional Results available

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
Device · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 18, 2026, 12:38 PM EDT
Terminated Phase 4 Interventional

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

NCT04413253
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast 5% Ophthalmic Solution, Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

NCT04669561
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Laguna Hills, California • Jacksonville, Florida • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

NCT00926185
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Terminated Phase 1 Interventional

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

NCT00936520
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 4 Interventional

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 18, 2026, 12:38 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

NCT04120987
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
60 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

NCT01421498
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

NCT04172961
View directory record Official record
Conditions
Dry Eye
Interventions
nanomicellular cyclosporine 0.09%, Lifitegrast
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

NCT07025811
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Vevye®, Xiidra®
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 18, 2026, 12:38 PM EDT
Not listed Not applicable Interventional

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

NCT03691636
View directory record Official record
Conditions
Dry Eye
Interventions
Eyelash prostheses, 5.0% Lifitegrast Ophthalmic Solution
Device
Lead sponsor
D.E.L., LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 18, 2026, 12:38 PM EDT
Withdrawn Phase 4 Interventional

Effect of Lifitegrast 5% on Tear Film Markers

NCT03952481
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes, Dry Eyes Chronic
Interventions
Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 4 Interventional

Treatment Regimens in Meibomian Gland Dysfunction

NCT05594745
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast Ophthalmic, Systane Free, Lipiflow
Drug · Device
Lead sponsor
Tauber Eye Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

NCT00882687
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Lifitegrast, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 18, 2026, 12:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

NCT04030962
View directory record Official record
Conditions
Dry Eye Disease, Dry Eye Syndrome
Interventions
AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 18, 2026, 12:38 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

NCT07490535
View directory record Official record
Conditions
Ocular Surface Disease, Dry Eye Syndrome (DES)
Interventions
(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
Drug
Lead sponsor
Pittsburgh Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sewickley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 18, 2026, 12:38 PM EDT